RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

NCT04625153 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Strategic Priority Adjustment

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: RC18 160mg
BIOLOGICAL: RC18 240mg

Sponsor

RemeGen Co., Ltd.